Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT03352765
What this trial is testing

A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

Who this might be right for
Lymphoma
Memorial Sloan Kettering Cancer Center 28
Testing effectiveness (Phase 2)Ended earlyNCT01159067
What this trial is testing

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

Who this might be right for
Iron OverloadAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in Remission+99 more
City of Hope Medical Center 1
Early research (Phase 1)Looking for participantsNCT05887167
What this trial is testing

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Who this might be right for
Hematologic MalignancyLarge B-cell LymphomaAcute Lymphoblastic Leukemia+3 more
Joshua Sasine, MD, PhD 20
Early research (Phase 1)Study completedNCT05182073
What this trial is testing

FT576 in Subjects With Multiple Myeloma

Who this might be right for
Multiple MyelomaMyeloma
Fate Therapeutics 31
Very early researchLooking for participantsNCT06999031
What this trial is testing

Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/RefractoryMultiple Myeloma
The First Affiliated Hospital of Nanchang University 12
Testing effectiveness (Phase 2)Looking for participantsNCT06832865
What this trial is testing

ELISA in Relapsed/Refractory MM

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)Relapsed Refractory Multiple Myeloma
Massachusetts General Hospital 30
Not applicableStudy completedNCT03188536
What this trial is testing

Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)

Who this might be right for
Multiple Myeloma
Takeda 282
Not applicableStudy completedNCT04458831
What this trial is testing

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Plasma Cell Myeloma
Sanofi 583
Very early researchUnknownNCT03943472
What this trial is testing

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hrain Biotechnology Co., Ltd. 10
Early research (Phase 1)UnknownNCT00821301
What this trial is testing

Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Immune Control 30
Testing effectiveness (Phase 2)Study completedNCT04176380
What this trial is testing

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Who this might be right for
Relapsed, Refractory Multiple Myeloma
Rapa Therapeutics LLC 15
Early research (Phase 1)Ended earlyNCT04702425
What this trial is testing

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Who this might be right for
Non-Hodgkin Lymphoma (NHL)Acute Myeloid Leukemia (AML)Multiple Myeloma (MM)
Novartis Pharmaceuticals 37
Testing effectiveness (Phase 2)UnknownNCT03090659
What this trial is testing

LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Who this might be right for
Refractory or Relapsed Multiple Myeloma
Nanjing Legend Biotech Co. 100
Not applicableLooking for participantsNCT07051850
What this trial is testing

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Who this might be right for
Multiple Myeloma, RelapsedMultiple Myeloma (MM)
Sung-Soo Park 174
Early research (Phase 1)WithdrawnNCT01680796
What this trial is testing

Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Florida
Early research (Phase 1)Active Not RecruitingNCT04184050
What this trial is testing

Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

Who this might be right for
Multiple Myeloma in RelapseMultiple MyelomaMultiple Myeloma of Bone+1 more
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT06523621
What this trial is testing

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Who this might be right for
Multiple Myeloma
Wake Forest University Health Sciences 1
Early research (Phase 1)Looking for participantsNCT06121843
What this trial is testing

Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 187
Not applicableStudy completedNCT03288974
What this trial is testing

Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea

Who this might be right for
Multiple Myeloma
Celgene 397
Large-scale testing (Phase 3)Active Not RecruitingNCT04975997
What this trial is testing

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Celgene 939
Next Page